Prophylactic Treatment of Pediatric Migraine: Is There Anything New in the Last Decade?

Research output: Contribution to journalReview article

Abstract

Migraine is a frequent and very disabling disease, especially at pediatric age. Despite this, there are few controlled data on the prophylactic treatment of primary headaches in this category of age. Given that the recently introduced calcitonin gene-related peptide (CGRP) inhibitors (CGRP-r) are still limited to adulthood, there is no drug with exclusive indication for migraine treatment in pediatric age. This raises several limitations in terms of adherence and effectiveness of the therapy. Moreover, the scenario is complicated by placebo response, which is larger in children and adolescents than in adults and often leads to an improvement in the attack frequency even in absence of any active pharmacological treatment. Our aim was to investigate the real evidence concerning the prophylactic therapy of pediatric migraine by reviewing the clinical studies published between 2010 and 2019.

Original languageEnglish
Pages (from-to)771
JournalFrontiers in Neurology
Volume10
DOIs
Publication statusPublished - 2019

Fingerprint

Migraine Disorders
Pediatrics
Therapeutics
Calcitonin Gene-Related Peptide
Headache
Placebos
Pharmacology
Pharmaceutical Preparations

Cite this

@article{5c840dc57f3a4cf3822b9a0844cdd3af,
title = "Prophylactic Treatment of Pediatric Migraine: Is There Anything New in the Last Decade?",
abstract = "Migraine is a frequent and very disabling disease, especially at pediatric age. Despite this, there are few controlled data on the prophylactic treatment of primary headaches in this category of age. Given that the recently introduced calcitonin gene-related peptide (CGRP) inhibitors (CGRP-r) are still limited to adulthood, there is no drug with exclusive indication for migraine treatment in pediatric age. This raises several limitations in terms of adherence and effectiveness of the therapy. Moreover, the scenario is complicated by placebo response, which is larger in children and adolescents than in adults and often leads to an improvement in the attack frequency even in absence of any active pharmacological treatment. Our aim was to investigate the real evidence concerning the prophylactic therapy of pediatric migraine by reviewing the clinical studies published between 2010 and 2019.",
author = "Laura Papetti and Fabiana Ursitti and Romina Moavero and Ferilli, {Michela Ada Noris} and Giorgia Sforza and Samuela Tarantino and Federico Vigevano and Massimiliano Valeriani",
year = "2019",
doi = "10.3389/fneur.2019.00771",
language = "English",
volume = "10",
pages = "771",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Prophylactic Treatment of Pediatric Migraine

T2 - Is There Anything New in the Last Decade?

AU - Papetti, Laura

AU - Ursitti, Fabiana

AU - Moavero, Romina

AU - Ferilli, Michela Ada Noris

AU - Sforza, Giorgia

AU - Tarantino, Samuela

AU - Vigevano, Federico

AU - Valeriani, Massimiliano

PY - 2019

Y1 - 2019

N2 - Migraine is a frequent and very disabling disease, especially at pediatric age. Despite this, there are few controlled data on the prophylactic treatment of primary headaches in this category of age. Given that the recently introduced calcitonin gene-related peptide (CGRP) inhibitors (CGRP-r) are still limited to adulthood, there is no drug with exclusive indication for migraine treatment in pediatric age. This raises several limitations in terms of adherence and effectiveness of the therapy. Moreover, the scenario is complicated by placebo response, which is larger in children and adolescents than in adults and often leads to an improvement in the attack frequency even in absence of any active pharmacological treatment. Our aim was to investigate the real evidence concerning the prophylactic therapy of pediatric migraine by reviewing the clinical studies published between 2010 and 2019.

AB - Migraine is a frequent and very disabling disease, especially at pediatric age. Despite this, there are few controlled data on the prophylactic treatment of primary headaches in this category of age. Given that the recently introduced calcitonin gene-related peptide (CGRP) inhibitors (CGRP-r) are still limited to adulthood, there is no drug with exclusive indication for migraine treatment in pediatric age. This raises several limitations in terms of adherence and effectiveness of the therapy. Moreover, the scenario is complicated by placebo response, which is larger in children and adolescents than in adults and often leads to an improvement in the attack frequency even in absence of any active pharmacological treatment. Our aim was to investigate the real evidence concerning the prophylactic therapy of pediatric migraine by reviewing the clinical studies published between 2010 and 2019.

U2 - 10.3389/fneur.2019.00771

DO - 10.3389/fneur.2019.00771

M3 - Review article

C2 - 31379721

VL - 10

SP - 771

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

ER -